EA200200301A1 - ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ - Google Patents

ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ

Info

Publication number
EA200200301A1
EA200200301A1 EA200200301A EA200200301A EA200200301A1 EA 200200301 A1 EA200200301 A1 EA 200200301A1 EA 200200301 A EA200200301 A EA 200200301A EA 200200301 A EA200200301 A EA 200200301A EA 200200301 A1 EA200200301 A1 EA 200200301A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted
collection center
cell death
present
inhibitors
Prior art date
Application number
EA200200301A
Other languages
English (en)
Inventor
Янь Ван
Эккард Вебер
Дуглас Р. Грин
Луфэн Гуань
Суй Хионг Кай
Гордон Б. Миллс
Original Assignee
Сайтовиэ, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайтовиэ, Инк. filed Critical Сайтовиэ, Инк.
Publication of EA200200301A1 publication Critical patent/EA200200301A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Данное изобретение направлено на новые замещенные α-гидроксикислоты, представленные общей формулой (I), в которой R-R, X и Z определены в данном контексте. Данное изобретение касается также обнаружения того факта, что соединения, имеющие формулу (I), являются сильными ингибиторами каспаз и апоптотической гибели клеток. Вследствие этого ингибиторы, соответствующие данному изобретению, могут замедлять или блокировать гибель клетки при ряде клинических состояний, при которых происходит утрата клеток, тканей или целых органов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200301A 1999-08-27 2000-08-28 ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ EA200200301A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15107799P 1999-08-27 1999-08-27
US15837399P 1999-10-12 1999-10-12
PCT/US2000/023566 WO2001016093A1 (en) 1999-08-27 2000-08-28 SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF

Publications (1)

Publication Number Publication Date
EA200200301A1 true EA200200301A1 (ru) 2002-08-29

Family

ID=26848309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200301A EA200200301A1 (ru) 1999-08-27 2000-08-28 ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ

Country Status (15)

Country Link
US (1) US6495522B1 (ru)
EP (1) EP1212295B1 (ru)
JP (1) JP2003508379A (ru)
KR (1) KR20020033777A (ru)
CN (1) CN1235875C (ru)
AT (1) ATE409688T1 (ru)
AU (1) AU775291B2 (ru)
BR (1) BR0013666A (ru)
CA (1) CA2383002A1 (ru)
DE (1) DE60040397D1 (ru)
EA (1) EA200200301A1 (ru)
IL (1) IL148426A0 (ru)
MX (1) MXPA02002038A (ru)
NO (1) NO20020938L (ru)
WO (1) WO2001016093A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
ATE276754T1 (de) * 1998-07-21 2004-10-15 Cytovia Inc Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
AU3876600A (en) * 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6355618B1 (en) * 1999-04-09 2002-03-12 Cytovia, Inc. Caspase inhibitors and the use thereof
AU2001249619B2 (en) 2000-03-29 2006-08-17 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20040198650A1 (en) * 2001-03-29 2004-10-07 Poul Jensen Means for inhibiting proteolytical processing of parkin
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
WO2002094263A2 (en) * 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003008373A1 (de) * 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
AU2003272189A1 (en) * 2002-04-05 2004-01-19 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
AU2003225088A1 (en) 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
EP1628674A2 (en) * 2003-05-06 2006-03-01 Cytovia, Inc. Protease inhibitors for coronaviruses and sars-cov and the use thereof
CA2557631A1 (en) * 2004-02-18 2005-09-01 Georgia Tech Research Corporation Propenoyl hydrazides
EP2399916B1 (en) * 2004-03-12 2014-12-10 Vertex Pharmaceuticals Incorporated Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors
WO2005115362A1 (en) 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
WO2009076598A1 (en) 2007-12-12 2009-06-18 Children's Hospital & Research Center At Oakland Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer
US8497307B2 (en) * 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
RU2703725C1 (ru) * 2013-11-21 2019-10-22 Аллерган, Инк. Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
CN104803864B (zh) * 2014-01-29 2017-01-11 华东师范大学 β-羟基-α-氨基酸衍生物及其合成方法和应用
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2381023A1 (fr) 1977-02-18 1978-09-15 Delalande Sa Nouveaux oligopeptides trifluoromethyles derives de la l-alanine, leur procede de preparation et leur application en therapeutique
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5221607A (en) 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US5252463A (en) 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
US5824297A (en) 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
AU3666893A (en) 1992-02-21 1993-09-13 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
CA2122227A1 (en) * 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US6087160A (en) 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
US5866545A (en) 1993-08-13 1999-02-02 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US5869519A (en) 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
AU738048B2 (en) 1996-09-12 2001-09-06 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
NZ330451A (ru) 1996-09-12 2000-01-28 Idun Pharmaceuticals Inc
US5877197A (en) 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
JPH111491A (ja) 1997-04-18 1999-01-06 Takeda Chem Ind Ltd ペプチド類及びその剤
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CN1138472C (zh) 1997-10-10 2004-02-18 西托维亚公司 二肽型编程性细胞死亡抑制剂及其用途
JPH11180891A (ja) 1997-12-25 1999-07-06 Dai Ichi Seiyaku Co Ltd 抗細胞死剤
KR20010041905A (ko) 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
ES2242394T3 (es) 1998-05-05 2005-11-01 Warner-Lambert Company Llc Inhibidores de tipo succinamida de la enzima convertidora de la interleuquina 1 beta.
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
CA2353079A1 (en) 1998-12-02 2000-06-08 Merck Frosst Canada Inc. Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
JP2002539193A (ja) 1999-03-16 2002-11-19 メルク フロスト カナダ アンド カンパニー カスパーゼ−３阻害薬としてのγ−ケト酸ジペプチド類
AU3876600A (en) 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6355618B1 (en) 1999-04-09 2002-03-12 Cytovia, Inc. Caspase inhibitors and the use thereof
DE60010675T2 (de) 1999-08-06 2005-06-16 Vertex Pharmaceuticals Inc., Cambridge Caspase inhibitoren und deren verwendung
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
AU2001249619B2 (en) 2000-03-29 2006-08-17 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
KR20020025959A (ko) 2000-05-23 2002-04-04 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 및 이의 용도
WO2001094351A1 (en) 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20020033777A (ko) 2002-05-07
US6495522B1 (en) 2002-12-17
IL148426A0 (en) 2002-09-12
WO2001016093A1 (en) 2001-03-08
EP1212295A1 (en) 2002-06-12
CA2383002A1 (en) 2001-03-08
EP1212295B1 (en) 2008-10-01
ATE409688T1 (de) 2008-10-15
CN1382119A (zh) 2002-11-27
DE60040397D1 (de) 2008-11-13
CN1235875C (zh) 2006-01-11
JP2003508379A (ja) 2003-03-04
NO20020938D0 (no) 2002-02-26
NO20020938L (no) 2002-04-15
MXPA02002038A (es) 2002-10-31
AU775291B2 (en) 2004-07-29
BR0013666A (pt) 2002-05-14
AU7080900A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
EA200200301A1 (ru) ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
DE60035037D1 (de) Caspase inhibitoren und ihre verwendung
EP1165490A4 (en) SUBSTITUTED 2-AMINOBENZAMINE CASPASE INHIBITORS AND THEIR USE
EP1076563A4 (en) DIPEPTID CASPASE INHIBITORS AND THEIR USE
WO2002100826A3 (en) Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
NO992617L (no) Sulfinsyrederivater, deres fremstilling og anvendelse
ATE309237T1 (de) Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
DK0931788T3 (da) Metalloproteasehæmmere
ATE267801T1 (de) N-alkanoylphenylalaninderivate
PT1230232E (pt) 4h-cromeno substituido e seus analogos como activadores de caspases e indutores de apoptose e sua utilizacao
ATE244699T1 (de) Substituierte anilinverbindungen
EP1392683A4 (en) SUBSTITUTED 4H-CHROMENS AND ANALOGS AS ACTIVATORS OF GASPASES AND INDUCTORS OF APOPTOSIS, AND THEIR USE
WO2001079187A8 (en) Substituted 1,4-thiazepine and analogs and their use as activators of caspases
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
SE0100326D0 (sv) New compounds
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
WO2002102301A3 (en) Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO1999065451A3 (en) Caspases and apoptosis
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
NO20042729L (no) Heksasykliske forbindelser
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
SE0101323D0 (sv) New process